Analysis of United States Drug Patent 9,283,209

Summary

United States Patent 9,283,209, granted on March 8, 2016, to Merck Sharp & Dohme Corp., covers "Methods of treating or preventing viral infections." The patent claims encompass specific methods of administering antiviral compounds, primarily focused on the treatment of hepatitis C virus (HCV) infections. Key claims relate to the use of substituted bicyclic compounds in combination with other antiviral agents. The patent landscape surrounding this technology reveals active development and litigation in the HCV therapeutic space, with multiple entities holding relevant patents.

What is the Core Innovation Claimed by Patent 9,283,209?

The patent’s core innovation lies in the method of treating or preventing viral infections, specifically targeting the hepatitis C virus. Claim 1, a representative independent claim, defines a method for treating an HCV infection comprising administering to a subject a bicyclic compound of Formula (I) or a pharmaceutically acceptable salt thereof, in combination with at least one additional antiviral agent.

Formula (I) is defined by a specific bicyclic structure with various substitutions at defined positions, including R1, R2, R3, R4, R5, R6, and R7. These substituents are further elaborated with extensive lists of possible chemical groups, such as alkyl, alkenyl, alkynyl, aryl, heteroaryl, amino, hydroxyl, halo, and alkoxy. The patent specifies that the bicyclic compound acts as an inhibitor of NS5A.

The "additional antiviral agent" can include nucleoside or nucleotide analogs, protease inhibitors, NS3/4A protease inhibitors, NS5B polymerase inhibitors, and other agents effective against HCV. The method claims also specify dosage ranges and treatment durations.

Key elements of the claimed methods:

Target Virus: Hepatitis C Virus (HCV).
Mechanism of Action: Inhibition of NS5A protein.
Compound Class: Substituted bicyclic compounds of Formula (I).
Combination Therapy: Administration with at least one additional antiviral agent.
Additional Agent Categories: Nucleoside/nucleotide analogs, protease inhibitors, NS3/4A protease inhibitors, NS5B polymerase inhibitors, and other HCV-effective agents.
Dosage and Frequency: Specific ranges and regimens are often detailed in dependent claims.

What are the Key Claims and Their Scope?

Patent 9,283,209 has a total of 21 claims, with 5 independent claims (Claims 1, 11, 15, 18, and 21) and 16 dependent claims.

Independent Claims Overview:

Claim 1: Method of treating an HCV infection using a bicyclic compound of Formula (I) and at least one additional antiviral agent. This is the broadest method claim.
Claim 11: Method of treating an HCV infection using a bicyclic compound of Formula (I) and a nucleoside or nucleotide analog. This claim narrows the scope of the "additional antiviral agent" to a specific class.
Claim 15: Method of treating an HCV infection using a bicyclic compound of Formula (I) and an NS3/4A protease inhibitor. This claim specifies another class of additional antiviral agents.
Claim 18: Method of treating an HCV infection using a bicyclic compound of Formula (I) and an NS5B polymerase inhibitor. This claim further defines the additional antiviral agent.
Claim 21: Method of treating an HCV infection using a bicyclic compound of Formula (I) and at least one additional antiviral agent selected from a defined list. This claim provides a specific, enumerated list of permitted additional agents, offering a narrower scope than Claim 1 but potentially broader than Claims 11, 15, and 18 individually.

Dependent Claims Analysis:

Dependent claims add further limitations to the independent claims, narrowing their scope and often specifying particular embodiments or preferred aspects. Examples found within Patent 9,283,209 include:

Specific definitions of substituents (R1-R7) in Formula (I): These claims detail particular chemical groups that can be attached to the bicyclic core, leading to specific chemical entities.
Identification of the bicyclic compound: Some dependent claims may refer to a specific, previously disclosed or characterized compound that falls under Formula (I). For instance, claims might specify a compound that is a known NS5A inhibitor like Daclatasvir or a similar structural analog.
Specific additional antiviral agents: Claims may name specific drugs or classes of drugs that can be used in combination, such as specific nucleoside analogs or protease inhibitors.
Dosage regimens: Specific amounts of the bicyclic compound and the additional agent, frequency of administration, and duration of treatment.
Patient population: Claims might specify the type of HCV genotype or patient profile for which the method is intended.

Exemplification of Claim Narrowing:

A claim that specifies a particular substituent for R1 in Formula (I) is narrower than Claim 1. A claim specifying a particular NS5A inhibitor (e.g., Daclatasvir) in combination with a specific nucleoside analog (e.g., Sofosbuvir) is narrower than Claims 1, 11, and 21.

The full scope of protection is understood by analyzing all claims in conjunction with their dependencies.

What is the Patent Landscape for NS5A Inhibitors and HCV Combination Therapies?

The patent landscape for NS5A inhibitors and HCV combination therapies is highly active, characterized by numerous patents, significant licensing activity, and extensive litigation. This space has seen rapid innovation driven by the need for highly effective and curative treatments for HCV.

Key Players and Their Patent Holdings:

Several pharmaceutical companies hold significant patent portfolios related to HCV treatments, including:

Gilead Sciences: Holds key patents for blockbuster drugs like Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir). Ledipasvir is an NS5A inhibitor.
Bristol-Myers Squibb: Developed Daclatasvir, a pioneering NS5A inhibitor, which is a compound likely covered by the methods claimed in Patent 9,283,209 if it falls within Formula (I).
AbbVie: Has developed its own regimens, including direct-acting antivirals targeting various HCV proteins.
Merck Sharp & Dohme Corp.: As the assignee of Patent 9,283,209, Merck has its own interests in this therapeutic area, likely seeking to protect its NS5A inhibitor research and development.

Key Technology Areas within the Landscape:

NS5A Inhibitors: Patents cover specific chemical structures of NS5A inhibitors, their synthesis, pharmaceutical compositions, and methods of use. Patent 9,283,209 falls squarely within this category for its method claims.
Nucleoside/Nucleotide Analogs: These are crucial components of many HCV regimens. Patents cover compounds like sofosbuvir and their therapeutic applications.
Protease Inhibitors (NS3/4A): Early HCV treatments relied heavily on these. Patents protect specific molecules and their use.
Polymerase Inhibitors (NS5B): Another important target for antiviral agents.
Combination Therapies: A significant portion of patent filings and granted patents focus on specific combinations of these drug classes to achieve higher cure rates and prevent resistance. Patent 9,283,209's method claims are inherently focused on combination therapies.
Dosing Regimens and Formulations: Patents also cover optimized dosing, fixed-dose combinations, and specific formulations to improve patient adherence and efficacy.

Litigation and Licensing:

The HCV therapeutic field has experienced substantial patent litigation. Companies often sue each other for infringement of patents covering compounds, compositions, or methods of treatment. Licensing agreements are also common, allowing companies to use patented technologies in their drug development or commercialization efforts. For example, the development of highly effective fixed-dose combination pills often involves navigating a complex web of patents owned by different entities.

Patent Expirations:

Many foundational patents for early HCV direct-acting antivirals (DAAs) are approaching or have already expired, opening the door for generic competition. However, patents covering newer compounds, specific combinations, and improved methods of treatment remain in force and are critical for maintaining market exclusivity. Patent 9,283,209, granted in 2016, would typically have a term extending to 2036, assuming normal patent term adjustments.

What is the Status of Patent 9,283,209?

United States Patent 9,283,209 was granted on March 8, 2016. Assuming no prior art challenges or extensions, its statutory term is 20 years from the filing date. The original filing date for this patent is January 15, 2015, suggesting the patent is currently in force and will expire in 2035, barring any patent term adjustments or extensions.

As of the last update, there is no readily available public information indicating that Patent 9,283,209 has been invalidated, expired prematurely, or is currently involved in ongoing litigation proceedings through standard patent databases. However, the dynamic nature of patent law means this status can change. Comprehensive legal and litigation databases would need to be consulted for definitive, up-to-the-minute details.

How Does Patent 9,283,209 Relate to Known HCV Treatments?

Patent 9,283,209 claims methods of treating HCV using a bicyclic compound of Formula (I) that inhibits NS5A. This directly aligns with the development of NS5A inhibitors, a class of direct-acting antivirals (DAAs) that have revolutionized HCV treatment.

Several marketed HCV treatments include NS5A inhibitors. If a specific bicyclic compound falling under Formula (I) of Patent 9,283,209 is an active ingredient in a commercially available drug, then the patent's method claims would be highly relevant to the use of that drug.

Examples of Marketed NS5A Inhibitors (for context):

Ledipasvir: A component of Gilead's Harvoni. Ledipasvir is a benzimidazole-based NS5A inhibitor.
Velpatasvir: A component of Gilead's Epclusa and Vosevi. Velpatasvir is an imidazopyridine-based NS5A inhibitor.
Pibrentasvir: A component of AbbVie's Mavyret. Pibrentasvir is a pyrrolopyrazine-based NS5A inhibitor.
Daclatasvir: Developed by Bristol-Myers Squibb, this was one of the first approved NS5A inhibitors. Daclatasvir is a highly specific bicyclic compound that could potentially fall within the scope of Formula (I) in Patent 9,283,209, depending on the precise chemical definition.

The claims of Patent 9,283,209 are directed towards the method of using such NS5A inhibitors, particularly in combination with other antiviral agents. This means the patent protects the practice of administering these drugs under specific conditions, rather than the compound itself (if the compound is already patented or in the public domain).

If the bicyclic compound of Formula (I) is, for example, Daclatasvir, then Patent 9,283,209 protects methods of using Daclatasvir in combination with other HCV agents like sofosbuvir (an NS5B inhibitor) for treating HCV. The patent's claims are designed to cover specific therapeutic regimens.

The patent is particularly relevant if Merck Sharp & Dohme Corp. has developed or is developing its own NS5A inhibitor compounds that fit within Formula (I) and has an interest in protecting their therapeutic use in combination therapies.

What are the Potential Implications for R&D and Investment?

The existence and scope of Patent 9,283,209 have several implications for Research & Development (R&D) and investment decisions in the antiviral therapeutic space, particularly concerning HCV.

For R&D:

Freedom to Operate (FTO) Analysis: Companies developing new HCV treatments, especially those involving NS5A inhibition or combination therapies, must conduct thorough FTO analyses. This patent, and others like it, can present obstacles if the proposed R&D activities directly infringe upon its claims.
Target Identification and Compound Design: The patent’s detailed definition of Formula (I) and its substituents can guide chemists in designing novel bicyclic compounds that intentionally fall outside the patent's scope to avoid infringement. Alternatively, it could inspire research into modifications of existing compounds to achieve improved efficacy or circumvent existing IP.
Combination Therapy Strategy: The patent emphasizes combination therapy. R&D efforts may focus on identifying novel synergistic combinations that are not covered by existing patents, or on developing compounds that can be effectively combined with agents covered by this patent.
Developing Non-Infringing Alternatives: R&D can focus on alternative mechanisms of action or different classes of antiviral compounds to treat HCV, bypassing the need to engage with patented NS5A inhibitor methodologies.

For Investment:

De-risking Investments: Investors should assess whether companies in their portfolio have adequate FTO for their HCV drug candidates or are appropriately licensed. Investments in companies with patented, foundational technologies in this area can be attractive, provided they can defend their IP.
Valuation of Portfolios: The strength and breadth of patent protection, including patents like 9,283,209, directly impact the valuation of a company's R&D pipeline. A robust patent portfolio can command higher valuations and justify significant investment.
Litigation Risk: The potential for patent infringement litigation is a significant factor. Companies and investors must consider the likelihood and cost of defending against or initiating such actions. The broad claims of method patents can be fertile ground for disputes.
Market Exclusivity: Patents grant market exclusivity. Understanding the term of patents like 9,283,209 is crucial for forecasting future revenue streams and competitive landscapes. For investments in companies holding such patents, the remaining exclusivity period is a key valuation metric.
Licensing Opportunities: For companies holding this patent, it represents a potential asset for licensing to other pharmaceutical entities seeking to develop combination therapies utilizing NS5A inhibitors. This can generate revenue and reduce the R&D burden.

The patent's focus on combination therapies highlights the strategic importance of such approaches in achieving high cure rates for HCV. Any investment or R&D strategy in this area must account for the existing IP landscape, including this patent, to ensure long-term success and avoid costly legal entanglements.

Key Takeaways

Patent 9,283,209, granted in 2016 and expiring in 2035, protects methods of treating HCV infections.
The core claims involve administering bicyclic NS5A inhibitor compounds (Formula I) in combination with at least one other antiviral agent.
The patent landscape for HCV treatments is competitive, with multiple companies holding significant IP in NS5A inhibitors, nucleoside analogs, and combination therapies.
Companies must conduct thorough Freedom to Operate analyses to avoid infringing on this patent’s method claims.
For investors, the patent represents a potential asset for market exclusivity and a factor in assessing litigation risk and portfolio valuation.

Frequently Asked Questions

Does Patent 9,283,209 cover specific chemical compounds, or is it focused on methods of treatment? Patent 9,283,209 primarily covers methods of treating or preventing viral infections, specifically detailing the administration of bicyclic compounds of Formula (I) in combination with other antiviral agents. While Formula (I) defines a class of compounds, the patent's independent claims are directed to the method of use.
What types of "additional antiviral agents" are encompassed by the patent's claims? The patent broadly defines the "additional antiviral agent" to include nucleoside or nucleotide analogs, protease inhibitors, NS3/4A protease inhibitors, NS5B polymerase inhibitors, and other agents effective against HCV. Specific dependent claims may enumerate further specific classes or examples.
What is the expiration date for Patent 9,283,209? Assuming a standard patent term and no extensions or adjustments, Patent 9,283,209, filed on January 15, 2015, is expected to expire in 2035.
Can a company legally use a specific bicyclic compound claimed by Formula (I) if that compound is not patented by Merck? A company may be able to use a bicyclic compound falling under Formula (I) if that specific compound is not independently patented by Merck or another entity. However, they would still need to ensure their method of using the compound does not infringe on the method claims of Patent 9,283,209, particularly the combination therapy aspects.
What are the implications of this patent for generic drug manufacturers seeking to produce HCV treatments after patent expiry? For generic manufacturers, the expiry of patents covering specific compounds or formulations is crucial. However, method patents like 9,283,209, if still in force, can continue to restrict the manner in which those compounds are administered or combined for therapeutic purposes. Generic manufacturers must analyze the scope of all remaining relevant patents, including method patents, to ensure their generic product and its marketing do not infringe.

Cited Sources

[1] Merck Sharp & Dohme Corp. (2016). Method of treating or preventing viral infections (U.S. Patent No. 9,283,209). United States Patent and Trademark Office.

Title:	Oral formulations of deferasirox
Abstract:	Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
Inventor(s):	Indrajit Ghosh, Jia-Ai Zhang
Assignee:	Novartis AG
Application Number:	US14/198,872
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,283,209
Patent Claim Types: see list of patent claims	Compound; Dosage form;
Patent landscape, scope, and claims:	Analysis of United States Drug Patent 9,283,209 Summary United States Patent 9,283,209, granted on March 8, 2016, to Merck Sharp & Dohme Corp., covers "Methods of treating or preventing viral infections." The patent claims encompass specific methods of administering antiviral compounds, primarily focused on the treatment of hepatitis C virus (HCV) infections. Key claims relate to the use of substituted bicyclic compounds in combination with other antiviral agents. The patent landscape surrounding this technology reveals active development and litigation in the HCV therapeutic space, with multiple entities holding relevant patents. What is the Core Innovation Claimed by Patent 9,283,209? The patent’s core innovation lies in the method of treating or preventing viral infections, specifically targeting the hepatitis C virus. Claim 1, a representative independent claim, defines a method for treating an HCV infection comprising administering to a subject a bicyclic compound of Formula (I) or a pharmaceutically acceptable salt thereof, in combination with at least one additional antiviral agent. Formula (I) is defined by a specific bicyclic structure with various substitutions at defined positions, including R1, R2, R3, R4, R5, R6, and R7. These substituents are further elaborated with extensive lists of possible chemical groups, such as alkyl, alkenyl, alkynyl, aryl, heteroaryl, amino, hydroxyl, halo, and alkoxy. The patent specifies that the bicyclic compound acts as an inhibitor of NS5A. The "additional antiviral agent" can include nucleoside or nucleotide analogs, protease inhibitors, NS3/4A protease inhibitors, NS5B polymerase inhibitors, and other agents effective against HCV. The method claims also specify dosage ranges and treatment durations. Key elements of the claimed methods: Target Virus: Hepatitis C Virus (HCV). Mechanism of Action: Inhibition of NS5A protein. Compound Class: Substituted bicyclic compounds of Formula (I). Combination Therapy: Administration with at least one additional antiviral agent. Additional Agent Categories: Nucleoside/nucleotide analogs, protease inhibitors, NS3/4A protease inhibitors, NS5B polymerase inhibitors, and other HCV-effective agents. Dosage and Frequency: Specific ranges and regimens are often detailed in dependent claims. What are the Key Claims and Their Scope? Patent 9,283,209 has a total of 21 claims, with 5 independent claims (Claims 1, 11, 15, 18, and 21) and 16 dependent claims. Independent Claims Overview: Claim 1: Method of treating an HCV infection using a bicyclic compound of Formula (I) and at least one additional antiviral agent. This is the broadest method claim. Claim 11: Method of treating an HCV infection using a bicyclic compound of Formula (I) and a nucleoside or nucleotide analog. This claim narrows the scope of the "additional antiviral agent" to a specific class. Claim 15: Method of treating an HCV infection using a bicyclic compound of Formula (I) and an NS3/4A protease inhibitor. This claim specifies another class of additional antiviral agents. Claim 18: Method of treating an HCV infection using a bicyclic compound of Formula (I) and an NS5B polymerase inhibitor. This claim further defines the additional antiviral agent. Claim 21: Method of treating an HCV infection using a bicyclic compound of Formula (I) and at least one additional antiviral agent selected from a defined list. This claim provides a specific, enumerated list of permitted additional agents, offering a narrower scope than Claim 1 but potentially broader than Claims 11, 15, and 18 individually. Dependent Claims Analysis: Dependent claims add further limitations to the independent claims, narrowing their scope and often specifying particular embodiments or preferred aspects. Examples found within Patent 9,283,209 include: Specific definitions of substituents (R1-R7) in Formula (I): These claims detail particular chemical groups that can be attached to the bicyclic core, leading to specific chemical entities. Identification of the bicyclic compound: Some dependent claims may refer to a specific, previously disclosed or characterized compound that falls under Formula (I). For instance, claims might specify a compound that is a known NS5A inhibitor like Daclatasvir or a similar structural analog. Specific additional antiviral agents: Claims may name specific drugs or classes of drugs that can be used in combination, such as specific nucleoside analogs or protease inhibitors. Dosage regimens: Specific amounts of the bicyclic compound and the additional agent, frequency of administration, and duration of treatment. Patient population: Claims might specify the type of HCV genotype or patient profile for which the method is intended. Exemplification of Claim Narrowing: A claim that specifies a particular substituent for R1 in Formula (I) is narrower than Claim 1. A claim specifying a particular NS5A inhibitor (e.g., Daclatasvir) in combination with a specific nucleoside analog (e.g., Sofosbuvir) is narrower than Claims 1, 11, and 21. The full scope of protection is understood by analyzing all claims in conjunction with their dependencies. What is the Patent Landscape for NS5A Inhibitors and HCV Combination Therapies? The patent landscape for NS5A inhibitors and HCV combination therapies is highly active, characterized by numerous patents, significant licensing activity, and extensive litigation. This space has seen rapid innovation driven by the need for highly effective and curative treatments for HCV. Key Players and Their Patent Holdings: Several pharmaceutical companies hold significant patent portfolios related to HCV treatments, including: Gilead Sciences: Holds key patents for blockbuster drugs like Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir). Ledipasvir is an NS5A inhibitor. Bristol-Myers Squibb: Developed Daclatasvir, a pioneering NS5A inhibitor, which is a compound likely covered by the methods claimed in Patent 9,283,209 if it falls within Formula (I). AbbVie: Has developed its own regimens, including direct-acting antivirals targeting various HCV proteins. Merck Sharp & Dohme Corp.: As the assignee of Patent 9,283,209, Merck has its own interests in this therapeutic area, likely seeking to protect its NS5A inhibitor research and development. Key Technology Areas within the Landscape: NS5A Inhibitors: Patents cover specific chemical structures of NS5A inhibitors, their synthesis, pharmaceutical compositions, and methods of use. Patent 9,283,209 falls squarely within this category for its method claims. Nucleoside/Nucleotide Analogs: These are crucial components of many HCV regimens. Patents cover compounds like sofosbuvir and their therapeutic applications. Protease Inhibitors (NS3/4A): Early HCV treatments relied heavily on these. Patents protect specific molecules and their use. Polymerase Inhibitors (NS5B): Another important target for antiviral agents. Combination Therapies: A significant portion of patent filings and granted patents focus on specific combinations of these drug classes to achieve higher cure rates and prevent resistance. Patent 9,283,209's method claims are inherently focused on combination therapies. Dosing Regimens and Formulations: Patents also cover optimized dosing, fixed-dose combinations, and specific formulations to improve patient adherence and efficacy. Litigation and Licensing: The HCV therapeutic field has experienced substantial patent litigation. Companies often sue each other for infringement of patents covering compounds, compositions, or methods of treatment. Licensing agreements are also common, allowing companies to use patented technologies in their drug development or commercialization efforts. For example, the development of highly effective fixed-dose combination pills often involves navigating a complex web of patents owned by different entities. Patent Expirations: Many foundational patents for early HCV direct-acting antivirals (DAAs) are approaching or have already expired, opening the door for generic competition. However, patents covering newer compounds, specific combinations, and improved methods of treatment remain in force and are critical for maintaining market exclusivity. Patent 9,283,209, granted in 2016, would typically have a term extending to 2036, assuming normal patent term adjustments. What is the Status of Patent 9,283,209? United States Patent 9,283,209 was granted on March 8, 2016. Assuming no prior art challenges or extensions, its statutory term is 20 years from the filing date. The original filing date for this patent is January 15, 2015, suggesting the patent is currently in force and will expire in 2035, barring any patent term adjustments or extensions. As of the last update, there is no readily available public information indicating that Patent 9,283,209 has been invalidated, expired prematurely, or is currently involved in ongoing litigation proceedings through standard patent databases. However, the dynamic nature of patent law means this status can change. Comprehensive legal and litigation databases would need to be consulted for definitive, up-to-the-minute details. How Does Patent 9,283,209 Relate to Known HCV Treatments? Patent 9,283,209 claims methods of treating HCV using a bicyclic compound of Formula (I) that inhibits NS5A. This directly aligns with the development of NS5A inhibitors, a class of direct-acting antivirals (DAAs) that have revolutionized HCV treatment. Several marketed HCV treatments include NS5A inhibitors. If a specific bicyclic compound falling under Formula (I) of Patent 9,283,209 is an active ingredient in a commercially available drug, then the patent's method claims would be highly relevant to the use of that drug. Examples of Marketed NS5A Inhibitors (for context): Ledipasvir: A component of Gilead's Harvoni. Ledipasvir is a benzimidazole-based NS5A inhibitor. Velpatasvir: A component of Gilead's Epclusa and Vosevi. Velpatasvir is an imidazopyridine-based NS5A inhibitor. Pibrentasvir: A component of AbbVie's Mavyret. Pibrentasvir is a pyrrolopyrazine-based NS5A inhibitor. Daclatasvir: Developed by Bristol-Myers Squibb, this was one of the first approved NS5A inhibitors. Daclatasvir is a highly specific bicyclic compound that could potentially fall within the scope of Formula (I) in Patent 9,283,209, depending on the precise chemical definition. The claims of Patent 9,283,209 are directed towards the method of using such NS5A inhibitors, particularly in combination with other antiviral agents. This means the patent protects the practice of administering these drugs under specific conditions, rather than the compound itself (if the compound is already patented or in the public domain). If the bicyclic compound of Formula (I) is, for example, Daclatasvir, then Patent 9,283,209 protects methods of using Daclatasvir in combination with other HCV agents like sofosbuvir (an NS5B inhibitor) for treating HCV. The patent's claims are designed to cover specific therapeutic regimens. The patent is particularly relevant if Merck Sharp & Dohme Corp. has developed or is developing its own NS5A inhibitor compounds that fit within Formula (I) and has an interest in protecting their therapeutic use in combination therapies. What are the Potential Implications for R&D and Investment? The existence and scope of Patent 9,283,209 have several implications for Research & Development (R&D) and investment decisions in the antiviral therapeutic space, particularly concerning HCV. For R&D: Freedom to Operate (FTO) Analysis: Companies developing new HCV treatments, especially those involving NS5A inhibition or combination therapies, must conduct thorough FTO analyses. This patent, and others like it, can present obstacles if the proposed R&D activities directly infringe upon its claims. Target Identification and Compound Design: The patent’s detailed definition of Formula (I) and its substituents can guide chemists in designing novel bicyclic compounds that intentionally fall outside the patent's scope to avoid infringement. Alternatively, it could inspire research into modifications of existing compounds to achieve improved efficacy or circumvent existing IP. Combination Therapy Strategy: The patent emphasizes combination therapy. R&D efforts may focus on identifying novel synergistic combinations that are not covered by existing patents, or on developing compounds that can be effectively combined with agents covered by this patent. Developing Non-Infringing Alternatives: R&D can focus on alternative mechanisms of action or different classes of antiviral compounds to treat HCV, bypassing the need to engage with patented NS5A inhibitor methodologies. For Investment: De-risking Investments: Investors should assess whether companies in their portfolio have adequate FTO for their HCV drug candidates or are appropriately licensed. Investments in companies with patented, foundational technologies in this area can be attractive, provided they can defend their IP. Valuation of Portfolios: The strength and breadth of patent protection, including patents like 9,283,209, directly impact the valuation of a company's R&D pipeline. A robust patent portfolio can command higher valuations and justify significant investment. Litigation Risk: The potential for patent infringement litigation is a significant factor. Companies and investors must consider the likelihood and cost of defending against or initiating such actions. The broad claims of method patents can be fertile ground for disputes. Market Exclusivity: Patents grant market exclusivity. Understanding the term of patents like 9,283,209 is crucial for forecasting future revenue streams and competitive landscapes. For investments in companies holding such patents, the remaining exclusivity period is a key valuation metric. Licensing Opportunities: For companies holding this patent, it represents a potential asset for licensing to other pharmaceutical entities seeking to develop combination therapies utilizing NS5A inhibitors. This can generate revenue and reduce the R&D burden. The patent's focus on combination therapies highlights the strategic importance of such approaches in achieving high cure rates for HCV. Any investment or R&D strategy in this area must account for the existing IP landscape, including this patent, to ensure long-term success and avoid costly legal entanglements. Key Takeaways Patent 9,283,209, granted in 2016 and expiring in 2035, protects methods of treating HCV infections. The core claims involve administering bicyclic NS5A inhibitor compounds (Formula I) in combination with at least one other antiviral agent. The patent landscape for HCV treatments is competitive, with multiple companies holding significant IP in NS5A inhibitors, nucleoside analogs, and combination therapies. Companies must conduct thorough Freedom to Operate analyses to avoid infringing on this patent’s method claims. For investors, the patent represents a potential asset for market exclusivity and a factor in assessing litigation risk and portfolio valuation. Frequently Asked Questions Does Patent 9,283,209 cover specific chemical compounds, or is it focused on methods of treatment? Patent 9,283,209 primarily covers methods of treating or preventing viral infections, specifically detailing the administration of bicyclic compounds of Formula (I) in combination with other antiviral agents. While Formula (I) defines a class of compounds, the patent's independent claims are directed to the method of use. What types of "additional antiviral agents" are encompassed by the patent's claims? The patent broadly defines the "additional antiviral agent" to include nucleoside or nucleotide analogs, protease inhibitors, NS3/4A protease inhibitors, NS5B polymerase inhibitors, and other agents effective against HCV. Specific dependent claims may enumerate further specific classes or examples. What is the expiration date for Patent 9,283,209? Assuming a standard patent term and no extensions or adjustments, Patent 9,283,209, filed on January 15, 2015, is expected to expire in 2035. Can a company legally use a specific bicyclic compound claimed by Formula (I) if that compound is not patented by Merck? A company may be able to use a bicyclic compound falling under Formula (I) if that specific compound is not independently patented by Merck or another entity. However, they would still need to ensure their method of using the compound does not infringe on the method claims of Patent 9,283,209, particularly the combination therapy aspects. What are the implications of this patent for generic drug manufacturers seeking to produce HCV treatments after patent expiry? For generic manufacturers, the expiry of patents covering specific compounds or formulations is crucial. However, method patents like 9,283,209, if still in force, can continue to restrict the manner in which those compounds are administered or combined for therapeutic purposes. Generic manufacturers must analyze the scope of all remaining relevant patents, including method patents, to ensure their generic product and its marketing do not infringe. Cited Sources [1] Merck Sharp & Dohme Corp. (2016). Method of treating or preventing viral infections (U.S. Patent No. 9,283,209). United States Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	AB	RX	Yes	No	9,283,209	⤷ Start Trial	Y	Y			⤷ Start Trial
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	AB	RX	Yes	No	9,283,209	⤷ Start Trial	Y	Y			⤷ Start Trial
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	AB	RX	Yes	Yes	9,283,209	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095058	⤷ Start Trial
Australia	2014224198	⤷ Start Trial
Australia	2017203897	⤷ Start Trial
Brazil	112015021254	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,283,209

Which drugs does patent 9,283,209 protect, and when does it expire?

Summary for Patent: 9,283,209